Table 1.
Baseline characteristics.
| Characteristics | Patients (n = 1179) |
|---|---|
| Age (years) | 50.2 ± 9.4 |
| <65 | 1102 (93.5) |
| ⩾65 | 65 (5.5) |
| Missing | 12 (1.0) |
| Menopause | |
| No | 449 (38.1) |
| Yes | 714 (60.6) |
| Missing | 16 (1.4) |
| Smoking history | |
| No | 1141 (96.8) |
| Yes | 22 (1.9) |
| Missing | 16 (1.4) |
| ECOG performance status | |
| 0 | 319 (27.1) |
| 1 | 800 (67.9) |
| 2 | 37 (3.1) |
| Missing | 23 (2.0) |
| Disease status | |
| Unresectable locally advanced | 235 (19.9) |
| Recurrent/metastatic | 944 (80.1) |
| Molecular subtype | |
| HR positive, HER2 negative | 341 (28.9) |
| HER2 positive | 436 (37.0) |
| Triple negative | 252 (21.4) |
| Missing | 150 (12.7) |
| Chemotherapy regimen | |
| LBP alone | 59 (5.0) |
| LBP + paclitaxel | 134 (11.4) |
| LBP + docetaxel | 263 (22.3) |
| LBP + gemcitabine | 237 (20.1) |
| LBP + vinorelbine | 403 (34.2) |
| Other LBP-based regimensa | 83 (7.0) |
| Treatment cycle | |
| 0 | 3 (0.3) |
| 1–3 | 239 (20.3) |
| 4 | 404 (34.3) |
| 5 | 262 (22.2) |
| 6 | 206 (17.5) |
| >6 | 63 (5.3) |
| Missing | 2 (0.2) |
Data were expressed as mean ± SD or n (%).
a
Other LBP-based regimens included LBP plus etoposide, LBP plus S-1, LBP plus irinotecan, LBP plus epirubicin, LBP plus pirarubicin, LBP plus doxorubicin, LBP plus cyclophosphamide, and LBP plus ifosfamide.
ECOG, Eastern Cooperative Oncology Group; HER2, human epidermal growth factor receptor 2; HR, hormone receptor; LBP, lobaplatin.